New York is currently home to 4451 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1b/2a, Where Patients Are Chosen Randomly to Test the Safety of SNIPR001 and to Assess How Well the Study Drug is Tolerated, How it is Absorbed in the Body and Its Initial Effectiveness in Patients With Certain Types of Blood Cancer
Recruiting
This is a Phase 1b/2a study in allogenic hematopoetic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: E Coli Infections
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
Recruiting
The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101. The main questions it aims to answer are: * Does ARD-101 improve the total score of the HQCT-9 (hyperphagia questionnaire for clinical trials, 9 questions)? * What medical problems do participants have when taking ARD-101? Researchers will compare ARD-101 to a placebo (a look-alike substance that con... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
04/21/2025
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Hyperphagia, Prader-Willi Syndrome
Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease
Recruiting
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Gender:
ALL
Ages:
Between 18 years and 67 years
Trial Updated:
04/21/2025
Locations: Scott Research, Inc., Laurelton, New York
Conditions: Proteinuric Kidney Disease
Luspatercept for Clonal Cytopenias of Uncertain Significance
Recruiting
The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Weill Cornell Medical College, New York, New York
Conditions: CCUS Clonal Cytopenia of Undetermined Significance, Anemia, Leukopenia, Thrombocytopenia, Neutropenia
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Recruiting
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Mount Sinai Tisch Cancer Center, New York, New York
Conditions: Advanced or Metastatic Solid Tumors
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia
Recruiting
Sphere-9 VT is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due to prior myocardial infarction will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/21/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Ventricular Tachycardia (VT)
Digoxin Medulloblastoma Study
Recruiting
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
04/21/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Recruiting
The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nephrectomy is a safe and effective treatment approach and if there is a change in the size of the tumor following immunotherapy prior to planned surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: Renal Cell Carcinoma
Mobile Cognitive Behavioral Therapy for Stroke
Recruiting
This study aims to assess the feasibility and acceptability of "MAYA", a mobile cognitive behavioral therapy app for anxiety and mood disorders, in adults who have had a stroke.
Gender:
ALL
Ages:
Between 40 years and 79 years
Trial Updated:
04/21/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Anxiety, Stroke, Depression
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Recruiting
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other me... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Prime Global Research ( Site 3731), Bronx, New York
Conditions: Coronavirus Disease (COVID-19)
BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study
Recruiting
This post-market study is being conducted to generate safety and performance data on the BD Prevue(TM) II Peripheral Vascular Access System with Cue(TM) Needle Tracking Technology. The data will be utilized to support regional registrations (for example, EU MDR), and document any unforeseen residual risks.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
04/21/2025
Locations: Brookdale University Hospital & Medical Center, Brooklyn, New York
Conditions: BD Prevue II for Peripheral Intravenous Catheter Placement
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Recruiting
This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \[EMD\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma